Status:
TERMINATED
Role of PWV on Male LUTS Progression
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Lower Urinary Tract Symptoms
Eligibility:
MALE
40-80 years
Brief Summary
Male lower urinary tract symptoms (LUTS) is exceedingly common in the general population. Stereotypically, male LUTS have long been attributed to the prostate. However, recent attention has been direc...
Detailed Description
Male-LUTS are prevalent, cause bother and impair quality of life (QoL). Not only does it adversely affect the quality of life of men, it is also closely interrelated with many substantial salient medi...
Eligibility Criteria
Inclusion
- Adult male subject aged between 40 and 80 years old.
- Able to consent to the study
Exclusion
- Have LUTS secondary to urethral stricture, neurogenic bladder or other structural abnormality
- Have known history of prostate cancer or bladder cancer
- Have been using 5α-reductase inhibitors for the management of male LUTS
- Have history of previous lower urinary tract (bladder, prostate, urethra) surgery or scheduled to have upcoming surgery
- Have history of other pelvic surgery that may affect voiding
- Have bladder stones or an active urinary tract infection within 8 weeks prior to recruitment for the study
- Subject is unable to complete questionnaires adopted in the study
Key Trial Info
Start Date :
May 11 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT04312074
Start Date
May 11 2020
End Date
December 31 2023
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, Hong Kong